Globaltraded.com , KSA — Avalon Pharma, a pharmaceutical company based in Saudi Arabia, has announced ambitious plans for international expansion. The company aims to triple its exports from 10% to 30% by the year 2030. To achieve this goal, Avalon Pharma plans to leverage its 25-year history in Saudi Arabia and expand into new international markets.
The expansion strategy involves refocusing efforts on strategic markets, particularly in the Gulf Cooperation Council (GCC) countries and Iraq. The company intends to introduce its expertise in health and prescription medicines to these markets, emphasizing innovation, research, and development.
Partnerships with distributors specific to each market will be a key aspect of Avalon Pharma’s expansion strategy. By collaborating with distributors, the company aims to strengthen its presence and distribution networks in target markets. The Saudi Export Development Authority (SEDA) is supporting Avalon Pharma in its expansion efforts, aligning with its mission to promote Saudi products in international markets.
Avalon Pharma has already made significant strides in the UAE, where it has partnered with City Pharmacy, the largest pharmaceutical distributor in the country. This partnership is expected to enhance Avalon Pharma’s footprint across the Emirates.
As part of its growth strategy, Avalon Pharma plans to re-establish its focus on key markets in the GCC. The company has also set up a regional office in Dubai, indicating its commitment to the region’s business community.
The pharmaceutical firm’s product portfolio includes cosmeceuticals, oral hygiene products, sanitizers, and herbal medicine. The company plans to expand its portfolio further and increase its stock. Additionally, Avalon Pharma aims to target emerging markets, particularly in East and West Africa, by promoting the “Made in Saudi” tagline attached to its products.
Avalon Pharma’s Chairman of the Board, Ahmad Al Tabbaa, highlighted the company’s success in the pharmaceutical industry, built over two decades in Saudi Arabia. The company’s growth strategy involves strengthening its presence in strategic markets, including the establishment of a country manager in Kuwait to serve Kuwait and Bahrain.
By capitalizing on its successful track record, partnerships with distributors, and support from SEDA, Avalon Pharma aims to play a significant role in advancing the global awareness of “Made in Saudi” products. GT)